Cannabidiol-drug interaction in cancer patients: A retrospective study in a real-life setting.
cannabidiol
herb-drug interaction
oncology
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
06
02
2023
received:
24
11
2022
accepted:
16
02
2023
medline:
19
6
2023
pubmed:
28
2
2023
entrez:
27
2
2023
Statut:
ppublish
Résumé
Cannabidiol (CBD) consumption in cancer patients is growing and there is a need to investigate how to detect cannabidiol-drug interactions (CDIs). However, CDIs and the clinical relevance between CBD, anticancer treatment, supportive care and conventional drugs is poorly studied especially in real-life settings. In 1 oncology day-hospital, a cross-sectional study in 363 cancer patients treated with chemotherapy revealed 20 patients (5.5%) who consumed CBD. In this study we aimed to explore the prevalence and clinical relevance of CDIs among these 20 patients. CDI detection used the Food and Drug Administration Drugs.com database and clinical relevance was assessed accordingly. Ninety CDIs with 34 medicines were detected (4.6 CDI/patient). The main clinical risks were central nervous system depression and hepatoxicity. The main CDIs were assessed as moderate and anticancer treatment do not seem to add to the risk. CBD discontinuation appears to be the most consistent management. Future studies should explore the clinical relevance of drug interactions with CBD in cancer patients.
Substances chimiques
Cannabidiol
19GBJ60SN5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2322-2328Informations de copyright
© 2023 British Pharmacological Society.
Références
Molassiotis A, Fernadez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005;16(4):655-663. doi:10.1093/annonc/mdi110
Zeller T, Muenstedt K, Stoll C, et al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol. 2013;139(3):357-365. doi:10.1007/s00432-012-1336-6
Ambrosone CB, Zirpoli GR, Hutson AD, et al. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). J Clin Oncol. 2020;38(8):804-814. doi:10.1200/JCO.19.01203
Pilla Reddy V, Jo H, Neuhoff S. Food constituent- and herb-drug interactions in oncology: influence of quantitative modelling on drug labelling. Br J Clin Pharmacol. 2021;87(10):3988-4000. doi:10.1111/bcp.14822
Clairet AL, Boiteux-Jurain M, Curtit E, et al. Interaction between phytotherapy and oral anticancer agents: prospective study and literature review. Med Oncol. 2019;36(5):45. doi:10.1007/s12032-019-1267-z
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and other protein targets - Alexander - 2019 Br J Pharmacol Wiley Online Library [Internet]. [cité 21 févr 2023]. Disponible sur: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14747, 176, Suppl 1, S1, S20.
Chan WJJ, Adiwidjaja J, McLachlan AJ, Boddy AV, Harnett JE. Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance. Cancer Chemother Pharmacol [Internet]. 2023 [cité 6 févr 2023; Disponible sur91(2):103-119. doi:10.1007/s00280-023-04504-z
Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst. 2008;100(11):773-783. doi:10.1093/jnci/djn148
Coveler AL, Mizrahi J, Eastman B, et al. Precision promise consortium pancreas cancer-associated pain management. Oncologist. 2021;26(6):e971-e982. doi:10.1002/onco.13796
Gilmartin CGS, Dowd Z, Parker APJ, Harijan P. Interaction of cannabidiol with other antiseizure medications: a narrative review. Seizure. 2021;86:189-196. doi:10.1016/j.seizure.2020.09.010
Sharoni SKA, Robani S, Zaini SA. Use of complementary and alternative medicine: prevalence and health literacy among patients attending a health centre in Universiti Teknologi MARA Selangor. Healthscope: The Official Research Book of Faculty of Health Sciences, UiTM [Internet]. 2019 [cité 25 févr 2022];1. Disponible sur: https://healthscopefsk.com/index.php/research/article/view/8 45.
Bar-Sela G, Cohen I, Campisi-Pinto S, et al. Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers (Basel). 2020;12(9):E2447. doi:10.3390/cancers12092447
Subbiah S, Presant CA, Upadhyaya G, Zheng M. Cannabis use patterns and patient reported outcomes in oncology and hematology patients: an anonymous survey. JCO. 2020;38(15_suppl):e24143. doi:10.1200/JCO.2020.38.15_suppl.e24143
Nielsen SW, Ruhlmann CH, Eckhoff L, Brønnum D, Herrstedt J, Dalton SO. Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences. Support Care Cancer févr. 2022;30(2):1181-1190. doi:10.1007/s00520-021-06515-z
Sukrueangkul A, Panomai N, Laohasiriwong W, Sakphisutthikul C, Phimha S. Factors influencing demand for medical cannabis use among cancer patients in the north of Thailand. Asian Pac J Cancer Prev. 2022;23(1):319-325. doi:10.31557/APJCP.2022.23.1.319
Davis MP. Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Canc Netw. 2016;14(7):915-922. doi:10.6004/jnccn.2016.0094
Sawtelle L, Holle LM. Use of cannabis and cannabinoids in patients with cancer. Ann Pharmacother. 2021;55(7):870-890. doi:10.1177/1060028020965224
Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metab Dispos. 2021;49(12):1070-1080. doi:10.1124/dmd.121.000442
Le Bozec A, Guedon M, Laurent M, et al. Prevalence of cannabidiol (CBD) consumption and cancer patients' expectations in one oncology day-hospital: a cross-sectional study. Eur J Oncol Pharm. 2022;1(suppl) abstract P068:44.
Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C. Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. J Oncol Pract. 2017;13(7):e613-e622. doi:10.1200/JOP.2017.020859
Wolf CPJG, Rachow T, Ernst T, et al. Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements. J Cancer Res Clin Oncol. 2022;148(2):461-473. doi:10.1007/s00432-021-03625-3
Zhu HJ, Wang JS, Markowitz JS, et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther. 2006;317(2):850-857. doi:10.1124/jpet.105.098541
Holland ML, Allen JD, Arnold JC. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008;591(1-3):128-131. doi:10.1016/j.ejphar.2008.06.079
Holland ML, Panetta JA, Hoskins JM, et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol. 2006;71(8):1146-1154. doi:10.1016/j.bcp.2005.12.033
Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332-338. doi:10.2133/dmpk.DMPK-12-RG-129
Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011;39(11):2049-2056. doi:10.1124/dmd.111.041384
Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88(15-16):730-736. doi:10.1016/j.lfs.2011.02.017
Patsalos PN, Szaflarski JP, Gidal B, VanLandingham K, Critchley D, Morrison G. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. Epilepsia. 2020;61(9):1854-1868. doi:10.1111/epi.16674
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome|NEJM [Internet]. [cité 18 sept 2022]. Disponible sur: https://www.nejm.org/doi/full/10.1056/nejmoa1611618
Ewing LE, Skinner CM, Quick CM, et al. Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model. Molecules. 2019;24(9):1694. doi:10.3390/molecules24091694
Silva GD, del Guerra FB, de Oliveira Lelis M, Pinto LF. Cannabidiol in the treatment of epilepsy: a focused review of evidence and gaps. Front Neurol. 2020;11:531939. doi:10.3389/fneur.2020.531939
Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies - PubMed [Internet]. [cité 18 sept 2022]. Disponible sur: https://pubmed.ncbi.nlm.nih.gov/30670598/